Malaga

• Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s … Recruiting
  2022-501606-35-01 11 2024-02-21 Platinum-sensitive epithelial ovarian, fallopian tube, or primary peri
• A Study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-po … Recruiting
  2023-505604-32-00 5 2024-01-24 Non small cell lung cancer (NSCLC)
• A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che … Recruiting
  2022-502660-20-00 5 2024-01-23 Follicular lymphoma
• A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N … Recruiting
  2023-503920-14-00 5 2024-01-02 Non-Small Cell Lung Cancer (NSCLC)
• Ulcerative Colitis: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Ulcerati … Recruiting
  2022-501788-41-00 5 2023-11-14 Ulcerative Colitis
• A Phase 3, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicit … Recruiting
  2022-501882-29-00 5 2023-11-03 Generalized Myasthenia Gravis (gMG)
• A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting
  2023-504247-13-00 4 2023-10-17 Small Cell Lung Cancer
• A study to learn how mRNA 4359 works in the body and how safe it is in participants with advanced solid tumor cancer when administered alone … Recruiting
  2023-504506-11-00 7 2023-10-09 Advanced Solid Tumors
• A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati … Recruiting
  2022-502959-54-00 5 2023-09-26 Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Ep
• A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Ca … Recruiting
  2022-501703-27-00 5 2023-07-05 Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
• Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting
  2022-500544-38-00 5 2023-06-05 Advanced Breast Cancer
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections
• A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with NMDAR or LGI1 mediated autoimm … Recruiting
  2023-504226-18-00 5 2022-11-30 NMDAR or LGI1 mediated autoimmune Encephalitis
• First in human study of BAY2927088 in participants who have advanced non-small cell lung cancer (NSCLC) with mutations in the genes of epide … Recruiting
  2023-503795-24-00 7 2022-09-16 Avanced Non-Small Cell Lung Cancer
• A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab. Recruiting
  2024-513185-19-00 9 2022-07-13 Extensive stage small cell lung cancer (ES-SCLC)
• OPEN LABEL, MAINTENANCE STUDY OF ORAL TOFACITINIB IN CHILDREN WITH MODERATE TO SEVERE ULCERATIVE COLITIS Recruiting
  2023-509694-22-00 5 2022-01-26 Ulcerative Colitis (UC)
• Study of efficacy and safety of iptacopan in complement 3 glomerulopathy patients Recruiting
  2023-509331-83-00 5 2021-07-28 complement 3 glomerulopathy
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer
• A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer Recruiting
  2025-522204-24-00 4 2026-06-16 Drug-Related Side Effects and Adverse Reactions
• A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu … Recruiting
  2025-521587-35-00 5 2026-06-03 Metastatic colorectal cancer
• SIE-1 Recruiting
  2025-523269-31-00 3 2026-06-02 Hormone receptor-positive early breast cancer in post-menopausal women
• A phase 3 trial comparing elritercept versus epoetin alfa for treatment of anemia due to lower-risk MDS in ESA-naïve adults who require RBC … Recruiting
  2025-523544-12-00 5 2026-06-02 Myelodysplastic neoplasms/syndromes (MDS)
• Optimising TREATment for severe Gram-Negative Bacterial infections. Recruiting
  2025-521476-65-00 6 2026-05-28 Severe Gram-Negative Bacterial infections
• Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer Recruiting
  2025-522888-15-00 3 2026-05-27 Small Cell Lung Cancer

Showing 169–192 of 1,056 trials